Donald Session
Medical · Montour Falls, NYNPI 1518102243
Payments from drug & device makers
Across 145 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$681
- Lilly USA, LLC$503
- Boehringer Ingelheim$398
- Novo Nordisk$323
- AbbVie$179
- Pfizer$166
- plus $477 from 8 others
What the payments were for
- Food & beverage$2,727100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $681 |
| Lilly USA, LLC | 26 | $503 |
| Boehringer Ingelheim | 19 | $398 |
| Novo Nordisk | 16 | $323 |
| AbbVie | 8 | $179 |
| Pfizer | 8 | $166 |
| Exact Sciences | 7 | $134 |
| Johnson & Johnson | 6 | $111 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $93 |
| Biohaven Pharmaceuticals, Inc. | 3 | $50 |
| Mylan Specialty L.p. | 3 | $42 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
How this compares
$2,727 in reported general payments places this provider in the 80th percentile of 2,395 medical providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 49 | $44,977 |
| JardianceEmpagliflozin | 34 | $27,211 |
| MounjaroTirzepatide | 21 | $26,913 |
| JanuviaSitagliptin Phosphate | 25 | $24,374 |
| FarxigaDapagliflozin Propanediol | 20 | $21,440 |
| RybelsusSemaglutide | 16 | $14,611 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 78 | $2,611 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,182 |
| Levothyroxine Sodium | 135 | $1,460 |
| FenofibrateFenofibrate Nanocrystallized | 70 | $1,405 |
| Tamsulosin Hcl | 106 | $1,310 |
| Atorvastatin Calcium | 148 | $1,080 |
| Omeprazole | 99 | $1,041 |
| Hydroxyzine Hcl | 14 | $836 |
| Acyclovir | 13 | $832 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $166 | $44,97749 claims |
| Boehringer IngelheimJardiance | $398 | $27,21134 claims |
| Lilly USA, LLCMounjaro | $503 | $26,91321 claims |
| AstraZenecaFarxiga | $681 | $21,44020 claims |
| Novo NordiskRybelsus | $323 | $14,61116 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $17 | $83213 claims |
| AbbVieSynthroid | $179 | $67916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,395 medical providers in New York.
Other medical in Montour Falls
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
- Hailey BrickmanNew York$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.